<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115338</article-id><article-id pub-id-type="publisher-id">ACM-42689</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_70119686.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  HBV相关肝癌的CD8+T细胞抗肿瘤免疫机制研究进展
  Research Progress on Anti-Tumor Immune Mechanism of CD8+T Cells in HBV-Related Hepatocellular Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>任</surname><given-names>丹丹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>金鑫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2347</fpage><lpage>2354</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  乙型肝炎病毒相关的肝细胞癌(HBV-HCC)通常被认为是与暴露于HBV和肿瘤抗原引发的慢性炎症相关的炎症相关的癌症。目前主要的治疗方案包括肝切除、肝移植、局部消融以及索拉菲尼化疗等方案。免疫治疗是一种新的治疗策略，通过增强机体自然免疫反应来治疗HBV-HCC，目前针对PD-1或CTLA-4的检查点阻断疗法已经在HCC患者中显示出初步的疗效。由于CD8+细胞毒性T淋巴细胞(CTLs)的产生在抗肿瘤免疫反应中起着重要作用，所以进一步探索HBV相关肝癌的CD8+T细胞抗肿瘤免疫机制非常必要。由于HBV相关肝癌的CD8+T细胞对HCC的免疫反应主要由病毒载量、肿瘤的抗原性以及癌症组织的微环境之间的平衡决定，本文将从HBV病毒载量、肿瘤抗原性以及肿瘤微环境三方面进行综述。
   Hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) is generally considered to be associated with chronic inflammation associated with exposure to HBV and tumor antigens. At present, the main treatment options include hepatectomy, liver transplantation, local ablation and sorafinib chemotherapy. Immunotherapy is a new treatment strategy to treat HBV-HCC, by enhancing the body’s natural immune response. At present, checkpoint blocking therapy for PD-1 or CTLA-4 has shown a preliminary effect in patients with HCC. Since the production of CD8+ cytotoxic T lymphocyte (CTLs) plays an important role in anti-tumor immune response, it is necessary to further explore the anti-tumor immune mechanism of CD8+T cells in HBV-related hepatocellular carcinoma. Since the immune response of CD8+T cells of HBV-related hepatocellular carcinoma to HCC is mainly determined by the balance among viral load, tumor antigenicity and cancer tissue microenvironment, this article will review the HBV viral load, tumor antigenicity and tumor microenvironment.
 
</p></abstract><kwd-group><kwd>乙型肝炎病毒，肝细胞癌，CD8+T细胞, Hepatitis B Virus</kwd><kwd> Hepatocellular Carcinoma</kwd><kwd> CD8+T Cell</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>乙型肝炎病毒相关的肝细胞癌(HBV-HCC)通常被认为是与暴露于HBV和肿瘤抗原引发的慢性炎症相关的炎症相关的癌症。目前主要的治疗方案包括肝切除、肝移植、局部消融以及索拉菲尼化疗等方案。免疫治疗是一种新的治疗策略，通过增强机体自然免疫反应来治疗HBV-HCC，目前针对PD-1或CTLA-4的检查点阻断疗法已经在HCC患者中显示出初步的疗效。由于CD8+细胞毒性T淋巴细胞(CTLs)的产生在抗肿瘤免疫反应中起着重要作用，所以进一步探索HBV相关肝癌的CD8+T细胞抗肿瘤免疫机制非常必要。由于HBV相关肝癌的CD8+T细胞对HCC的免疫反应主要由病毒载量、肿瘤的抗原性以及癌症组织的微环境之间的平衡决定，本文将从HBV病毒载量、肿瘤抗原性以及肿瘤微环境三方面进行综述。</p></sec><sec id="s2"><title>关键词</title><p>乙型肝炎病毒，肝细胞癌，CD8+T细胞</p></sec><sec id="s3"><title>Research Progress on Anti-Tumor Immune Mechanism of CD8+T Cells in HBV-Related Hepatocellular Carcinoma</title><p>Dandan Ren<sup>*</sup>, Jinxin Ma<sup>#</sup></p><p>Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/47-1572215x5_hanspub.png" /></p><p>Received: Apr. 25<sup>th</sup>, 2021; accepted: May 8<sup>th</sup>, 2021; published: May 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/47-1572215x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) is generally considered to be associated with chronic inflammation associated with exposure to HBV and tumor antigens. At present, the main treatment options include hepatectomy, liver transplantation, local ablation and sorafinib chemotherapy. Immunotherapy is a new treatment strategy to treat HBV-HCC, by enhancing the body’s natural immune response. At present, checkpoint blocking therapy for PD-1 or CTLA-4 has shown a preliminary effect in patients with HCC. Since the production of CD8+ cytotoxic T lymphocyte (CTLs) plays an important role in anti-tumor immune response, it is necessary to further explore the anti-tumor immune mechanism of CD8+T cells in HBV-related hepatocellular carcinoma. Since the immune response of CD8+T cells of HBV-related hepatocellular carcinoma to HCC is mainly determined by the balance among viral load, tumor antigenicity and cancer tissue microenvironment, this article will review the HBV viral load, tumor antigenicity and tumor microenvironment.</p><p>Keywords:Hepatitis B Virus, Hepatocellular Carcinoma, CD8+T Cell</p><disp-formula id="hanspub.42689-formula86"><graphic xlink:href="//html.hanspub.org/file/47-1572215x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/47-1572215x8_hanspub.png" /> <img src="//html.hanspub.org/file/47-1572215x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 背景介绍</title><p>肝癌被预测为2018年第六大最常见的癌症和第四大癌症死亡原因，每年约有84.1万新病例和78.2万人死亡 [<xref ref-type="bibr" rid="hanspub.42689-ref1">1</xref>]。在各种类型的原发性肝脏恶性肿瘤中，肝细胞癌(HCC)是最常见的，约占病例的75%~85% [<xref ref-type="bibr" rid="hanspub.42689-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42689-ref2">2</xref>]。慢性乙型肝炎病毒(HBV)感染一直被认为是HCC发生的主要危险因素，占全世界HCC病例的50%以上 [<xref ref-type="bibr" rid="hanspub.42689-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.42689-ref4">4</xref>]。世界上HBsAg的流行率很高，尤其是东亚地区。至少有1.2亿中国人携带HBsAg，这使中国成为一个高度流行的地区。值得注意的是，慢性HBV携带者患肝癌的潜在风险是未感染人群的几十倍。程序性细胞死亡蛋白-1 (PD-1)是一种表达在B细胞、T细胞、树突状细胞和自然杀伤(NK) T细胞上的免疫抑制分子，可抑制抗癌免疫，已被证明与HCC的病程和HBV感染有关。目前，阻断PD-1/程序性死亡配体1 (PD-L1)通路已成为调节宿主免疫反应、抑制各种类型肿瘤发展的一种有前途的、有利的免疫治疗方法。众所周知，CD8+细胞毒性T淋巴细胞(CTLs)的产生在抗肿瘤免疫反应中起着重要作用，目前相关的研究主要集中在HBV病毒载量、肿瘤抗原性以及肿瘤微环境三方面。</p></sec><sec id="s6"><title>2. HBV DNA</title><p>HBV DNA即是乙肝病毒的脱氧核糖核酸(即乙肝病毒基因)。HBV-DNA是HBV感染最直接、特异性强和灵敏性高的指标，HBV-DNA阳性，提示HBV复制和有传染性。HBV-DNA越高表示病毒复制越厉害，传染性强。在HBV急性感染期间，一般会在感染几周后可以检测到多特异性的、多功能的乙肝病毒特异性T细胞，然而，在慢性乙型肝炎(CHB)患者和HBV-HCC患者中，HBV特异性CD8(+)T细胞频率的检测率非常低 [<xref ref-type="bibr" rid="hanspub.42689-ref5">5</xref>]。这可能是因为CHB患者和HBV-HCC患者中通常表现为无效的CD8+T细胞反应。CD8+T细胞失效的一个原因是病毒序列突变的出现，这可能导致抗病毒CD8+T细胞失去识别能力从而没有被APC充分激活。另一个关键决定因素是一种称为T细胞衰竭的现象，即病毒特异性CD8+T细胞抗病毒效应功能逐渐丧失，包括细胞因子产生减少、细胞毒性降低和增殖能力受损 [<xref ref-type="bibr" rid="hanspub.42689-ref6">6</xref>]。Li Z [<xref ref-type="bibr" rid="hanspub.42689-ref7">7</xref>] 等对8例未经治疗的HCC患者肿瘤浸润的CD8+T细胞和从其他组织来源(瘤周组织)分离的CD8+T细胞进行了外显子组和转录组全序列测定。肿瘤浸润的CD8+T细胞在个体间也表现出较大的转录异质性，这受HBVDNA水平、术前抗病毒治疗和T细胞浸润程度等临床特征的调节。HBV病毒载量可能在某种程度上反映了抗肿瘤免疫活性，因为HBV水平低的患者往往表现出更高的T细胞增殖信号的表达。Witjes等 [<xref ref-type="bibr" rid="hanspub.42689-ref8">8</xref>] 研究了肝癌患者HBV DNA水平是否影响患者的生存，对高病毒载量(HBV DNA &gt; 105拷贝/ml)和低病毒载量(HBV DNA &lt; 105拷贝/ml)的肝癌患者的生存率进行评估，发现病毒载量高的肝癌患者1年和5年生存率分别为58%和11%，病毒载量低的肝癌患者的1年和5年生存率分别为70%和35%。即HBV DNA水平与HCC患者的总体生存率相关。Huang S [<xref ref-type="bibr" rid="hanspub.42689-ref9">9</xref>] 等在探讨抗病毒治疗(AVT)对复发性乙型肝炎病毒(HBV)相关性肝细胞癌(HCC)患者再次肝切除术后近期和远期疗效的影响的研究中纳入583名因初次肝切除术后HBV相关性肝癌肝内复发而接受再次肝切除术的患者，发现术前抗病毒治疗降低了病毒复发率，再次肝切除前后启动AVT有助于HBV相关复发HCC再次肝切除后更好的远期预后。上述研究表明血清HBV病毒载量可用于患者的免疫反应评估，在肝切除治疗中联合抗病毒药物治疗可能有利于HBV相关HCC患者的T细胞激活。总体而言，HBV病毒载量和抗病毒治疗可能会影响HCC的T细胞功能状态，进一步的大样本研究可能是有价值的。</p></sec><sec id="s7"><title>3. 肿瘤抗原性</title><p>目前报道的最多的针对HBV相关肝癌的抗原靶点包括病毒抗原、肿瘤相关抗原(TAA)、新抗原和细菌相关性抗原。HBV整合到宿主基因组中，肝细胞癌患者的肿瘤细胞表达的HBV蛋白在患者体内可引发高亲和力的T细胞反应。TAAs是来源于内源性野生型蛋白质的表位，其在肿瘤中的表达增加，在健康组织中的数量或空间表达受到限制 [<xref ref-type="bibr" rid="hanspub.42689-ref10">10</xref>]。目前针对HBV相关肝癌的病毒抗原和肿瘤相关抗原的免疫优势和功能仍然不太清楚。Gehring A [<xref ref-type="bibr" rid="hanspub.42689-ref11">11</xref>] 等用酶联免疫吸附斑点技术(ELISPOT)对10例肝细胞癌、10例乙肝肝硬变、10例乙肝但无肝硬变的细胞扩增后进行分析发现，大多数肝癌患者(总共7/10)确实有可检测到的TAA特异性T细胞，其中肿瘤抗原NY-ESO-1和SSX-2是最常见的靶点，然而却很少检测到乙肝病毒特异性反应。Inada Y等 [<xref ref-type="bibr" rid="hanspub.42689-ref12">12</xref>] 分析了32例乙型肝炎病毒(HBV)相关性肝癌、42例丙型肝炎病毒相关性肝癌和18例非酒精性脂肪性肝炎(NASH)相关性肝癌患者的临床资料。发现HBV、丙型肝炎和NASH相关的HCC群体对TAAs的免疫应答不同。具体而言，对p53和MRP3的免疫反应为在与HBV相关的HCC组中观察到高频率，对甲胎蛋白的反应为在丙型肝炎病毒相关的HCC组中观察到高频率。在NASH相关的HCC组中，只有6例(33.3%)检测到对至少一种TAA病毒的免疫应答这一频率低于HBV相关的HCC组(22/32, 68.8%)和丙型肝炎相关的HCC组(32/42, 76.2%)，这表明NASH相关的HCC免疫原性低。上述研究表明HBV特异性CD8+T细胞虽然能控制肿瘤的生长，但是由于病毒慢性感染的原因，乙肝病毒特异性T细胞被耗尽或缺失，所以失去控制肿瘤生长的能力。TAA特异性CD8+T细胞虽然耗竭的程度相对较轻，但是肿瘤相关抗原的TCR亲和力较低，再加上TAA表达较少，所以可能限制了其控制肿瘤的能力。目前正在进行的针对HBV抗原和肿瘤相关抗原的过继T细胞免疫疗法，即通过引入嵌合抗原受体或已知特异性的TCR来重新定向患者血液中T细胞的特异性，可能可以解决HBV相关肝癌患者病毒特异性T细胞耗竭以及TAA亲和力低的问题。除了病毒抗原和肿瘤抗原外，新抗原也渐渐得到关注，即通过对肿瘤进行广泛的遗传和免疫学表征，以发现免疫原性HCC特异性新抗原。这些自身抗原随着特定肿瘤的发展而变异，使它们在免疫学上不同于自然产生的变异，因此更具肿瘤特异性。但是发现特定新抗原的过程非常复杂，涉及基因测序，然后是新抗原免疫原性的计算预测或广泛的实验验证，再加上新抗原的个人化性质，即突变主要是患者特有的，将这种方法转化到临床上是很繁琐的。Yang H [<xref ref-type="bibr" rid="hanspub.42689-ref13">13</xref>] 等发现携带TP53新抗原的HCC患者总生存期比其他患者长(p = 0.0371)，他们表现出更高的免疫评分(p = 0.0441)，更高的细胞毒性淋巴细胞浸润(p = 0.0428)，即TP53新抗原可能成为肝癌免疫治疗的潜在靶点。肝脏是受影响的主要器官，通过肝门静脉血从肠道接收食物营养和微生物代谢物，因此是微生物抗原和T细胞反应相互作用的潜在场所。Rong Y [<xref ref-type="bibr" rid="hanspub.42689-ref14">14</xref>] 等检测了HBV相关HCC患者的细菌反应性CD8+ T细胞反应，发现来自HBV相关HCC患者的循环CD8+ T细胞表现出显著升高的细菌反应性，观察到CD8+ T细胞与Foxp3+调节性T细胞的比例与长双歧杆菌反应性和肠球菌反应性CD8+ T细胞的比例呈正相关，而PD-1+ CD8+ T细胞的频率与肠球菌反应性CD8+ T细胞的频率呈负相关。此外，HCC患者肿瘤切除后的无病生存期与双歧杆菌的出现频率呈正相关。目前尚不清楚细菌反应性CD8+ T细胞是否能通过直接消除肿瘤细胞或支持抗肿瘤免疫的其他分支积极发挥抗肿瘤功能，相关报道较少，所以还需要在控制良好的动物模型中进行进一步的研究。</p></sec><sec id="s8"><title>4. 肿瘤微环境</title><p>HBV病毒通过引起异常的免疫应答导致肝细胞损伤及炎症坏死，炎症坏死持续存在或反复发现可诱导肝脏免疫抑制从而导致免疫耐受。最后由于免疫监视功能受损介导了肿瘤的发生，从而产生了所谓的肿瘤微环境。这种微环境由与健康状态下的肝脏相似的免疫成分组成，但具有不同的局部募集、细胞干扰和免疫解剖。从健康肝脏到肿瘤微环境的渐进转化是通过持续干扰肝脏的正常免疫稳态实现的，特别是通过免疫抑制细胞因子的分泌、抗原的异常表达和炎症状态下局部免疫细胞干扰的变化。除了HCC免疫调节之外，癌细胞在根据其代谢需求形成微环境方面也起着重要作用。</p><sec id="s8_1"><title>4.1. 免疫检查点</title><p>免疫系统是身体中的细胞，组织和器官的集合，可以抵御“外来”入侵者的攻击。一旦入侵者被识别，免疫反应就被触发。在用T细胞受体和共信号分子识别抗原呈递细胞(APC)上的主要组织相容性复合物(MHC)分子后，T细胞被激活。在人体中，需要微调免疫反应，因为过强的免疫反应可能导致身体攻击其自身的健康组织和细胞，而弱免疫反应则无法保护身体免受入侵者的侵害。免疫系统有自己的免疫调节控制点，称为免疫检查点 [<xref ref-type="bibr" rid="hanspub.42689-ref15">15</xref>]。虽然通过靶向程序性细胞死亡-1 (PD-1)/PD-L1、CTLA-4增强免疫反应的免疫疗法正在应用于HCC [<xref ref-type="bibr" rid="hanspub.42689-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42689-ref17">17</xref>]，但这些治疗显示出有限的反应率，表明额外的抑制受体也参与了T细胞耗竭和肿瘤预后。Liu X [<xref ref-type="bibr" rid="hanspub.42689-ref18">18</xref>] 等发现HBV-HCC患者的CD4+和CD8+ T细胞上PD-1和T细胞免疫球蛋白以及免疫受体酪氨酸基抑制基序域(TIGIT)的共表达与慢性HBV或HBV肝硬化患者的共表达相比显著上调。重要的是，PD-1+ TIGIT+ CD8+ T细胞群与总生存率和无进展生存率呈负相关。Liu F [<xref ref-type="bibr" rid="hanspub.42689-ref19">19</xref>] 等纳入90例HBV相关性肝癌患者作为研究对象，发现HBV-HCC患者TIL上T细胞Ig和粘蛋白结构域包含分子-3 (Tim-3)和/或PD-1的表达损害其功能，与无瘤生存期呈负相关。直接阻断TIM-3和PD-1可以恢复TIL的抗肿瘤作用，为HBV-HCC的免疫治疗提供了新的靶点。在慢性HBV感染过程中，还有其他几种受体可以削弱T细胞的反应，如CD244(2B4)、BTLA、LAG-3、CD160等 [<xref ref-type="bibr" rid="hanspub.42689-ref20">20</xref>]。上述这些抑制性受体可能单独或与其他抑制分子共同作用于HBV相关HCC患者的T细胞耗竭。所以通过抑制这些抑制性受体来恢复T细胞功能可能成为HBV相关HCC免疫治疗的潜在靶点。Otano I [<xref ref-type="bibr" rid="hanspub.42689-ref21">21</xref>] 等对HBV相关HCC病毒抗原特异性T细胞开发了一种新的慢病毒转导方案，以实现内源性或TCR重定向的抗原特异性PD-1敲除的CD8+ T细胞，发现人T细胞的PD-1敲除可增强抗肿瘤效应细胞的功能，并促进了肝癌细胞的杀伤能力。检查点分子的阻断疗法和TCR-T细胞疗法的联合策略可能是一种很有潜力的增强CD8+T细胞抗肿瘤免疫的疗法，但是还需要在更大的临床试验中进行验证。</p></sec><sec id="s8_2"><title>4.2. 相关免疫细胞</title><p>Lim C [<xref ref-type="bibr" rid="hanspub.42689-ref22">22</xref>] 等通过结合细胞因子、下一代测序和多重组织免疫荧光的方法，比较了HBV相关和非病毒相关肝细胞癌。在HBV相关的HCC中观察到调节性T淋巴细胞(Tregs)和T细胞驻留记忆细胞相对富集，而TIM3+CD8+细胞和表达活化受体CD244的自然杀伤细胞(NK)在与病毒感染无关的肝细胞中更丰富，而且HBV相关的肝癌中PD-1表达更多，似乎含有更多的免疫抑制或衰竭浸润。此外，在这项研究中，较高的Treg含量与较短的总生存期相关，而高含量的常驻记忆T细胞预示着较好的生存期。调节性T细胞(Tregs)是CD4+T细胞的亚群，由CD25标记物识别。先天缺乏Tregs细胞是免疫失调、多内分泌疾病、肠病、X连锁综合征患者严重自身免疫性炎症的原因。越来越多的证据表明Tregs可通过白细胞介素-2 (IL-2)、白细胞介素-10 (IL-10)和转化生长因子-β (TGF-β)等免疫抑制性因子以及细胞接触介导的调节等多种机制来实现其免疫抑制的能力，即可以削弱抗肿瘤免疫，帮助肿瘤细胞逃脱免疫监视 [<xref ref-type="bibr" rid="hanspub.42689-ref23">23</xref>]。这种免疫抑制可能是目前使用的一些免疫疗法结果不佳的原因。Tregs可能是免疫治疗的潜在靶点。然而，还没有成功的临床试验报道，可能是因为仅耗尽Tregs不足以防止肿瘤介导的免疫抑制。所以更好地了解HCC Tregs细胞的作用对于设计未来基于免疫治疗的临床方案非常重要。Song G [<xref ref-type="bibr" rid="hanspub.42689-ref24">24</xref>] 等对来自7对HBV/HCV相关HCC肿瘤和非肿瘤肝组织的41,698个免疫细胞进行了单细胞RNA测序，发现M2巨噬细胞的一个亚群，其高表达CCL18和转录因子CREM，在晚期HCC患者中富集，并可能参与肿瘤进展。与CHB相比，HBV相关HCC的骨髓源性抑制细胞(MDSCs)的百分比较高。MDSCs促进了持续的免疫抑制效应，可能在慢性HBV感染向HCC的转化过程中可能起重要作用 [<xref ref-type="bibr" rid="hanspub.42689-ref25">25</xref>]。最近的一项研究显示，HCC不同亚型的肿瘤浸润性白细胞组成不同。对于无复发生存期(RFS)，CD8+T细胞和M0巨噬细胞是HBV-HCC的潜在生物标志物，而中性粒细胞是HCV-HCC的独立预测因子 [<xref ref-type="bibr" rid="hanspub.42689-ref26">26</xref>]。总之，与HBV相关的HCC的TME被认为比与HBV无关的HCC的免疫抑制作用更强、更疲惫。未来的工作将需要在更大的队列中进行，以探索这些免疫细胞在HBV相关肝癌的具体作用，或许有助于开发新的治疗靶点和策略。</p></sec><sec id="s8_3"><title>4.3. 相关细胞因子</title><p>细胞因子是促进免疫细胞通讯、激活、分化和失活的分子。促炎症细胞因子和抗炎细胞因子在T细胞功能中的作用已被广泛研究。Shi JX [<xref ref-type="bibr" rid="hanspub.42689-ref27">27</xref>] 等在一项探讨IL-22在肝癌发生发展过程中的重要性，以及IL-22水平与肝癌预后的关系的研究中，发现从慢性乙型肝炎到急性肝炎和肝癌，肝脏浸润的IL-22细胞呈递增趋势(慢性乙型肝炎与急性肝炎比较，P = 0.002；急性肝炎与肝癌比较，P = 0.010)，而CD8T细胞呈下降趋势(慢性乙型肝炎与急性肝炎比较，P = 0.031；急性肝炎与肝癌比较，P = 0.652)。这些发现表明IL-22促进了慢性乙型肝炎患者肝细胞癌的进展。肿瘤浸润的高IL-22细胞和血清IL-22水平被认为是肝癌的不良预后指标。其他细胞因子包括转化生长因子-β、IL-2、IL-6、IL-8、IL-10、IDO、精氨酸酶、腺苷、乳酸、血管内皮生长因子、血小板衍生生长因子、表皮生长因子受体配体等也有助于肝癌组织免疫抑制环境的建立，它们也被认为是慢性HBV感染及HCC的关键介质，值得进一步研究 [<xref ref-type="bibr" rid="hanspub.42689-ref28">28</xref>]。</p></sec><sec id="s8_4"><title>4.4. 有氧糖酵解</title><p>Wang Y [<xref ref-type="bibr" rid="hanspub.42689-ref29">29</xref>] 等使用RNA-seq测序法比较健康献血者血液、HCC患者肿瘤组织和慢性HBV相关HCC患者癌旁组织中CD8+T细胞的转录组，发现CHB和HCC之间有将近一半的差异表达基因是共有的，这表明在这两种情况下发生的T细胞功能障碍是高度相同的，但仍然各有其特定的属性。与慢性HBV相关HCC患者癌旁组织中CD8+T细胞相比，帕金森病、氧化磷酸化和实体瘤相关基因被确定为HCC所特有的失去调控的基因，表明HCC的T细胞功能障碍与其他实体瘤高度相似，而且与异常的氧化磷酸化密切相关。“沃伯格效应”表明肿瘤细胞倾向于选择有氧糖酵解而不是氧化磷酸化(OXPHOS)，这与肿瘤微环境的特征密切相关(TME) [<xref ref-type="bibr" rid="hanspub.42689-ref30">30</xref>]。HCC微环境包括缺氧、酸中毒和免疫抑制，有助于肿瘤糖酵解。反过来，肿瘤的糖酵解加剧缺氧、酸中毒和免疫抑制，并导致肿瘤增殖、血管生成、上皮–间质转化(EMT)、侵袭和转移 [<xref ref-type="bibr" rid="hanspub.42689-ref31">31</xref>]。肝脏作为体内的主要代谢器官，通过调节糖原的合成和分解，在葡萄糖稳态中起着重要作用。禁食期间，约80%的内源性葡萄糖由肝脏通过糖异生产生 [<xref ref-type="bibr" rid="hanspub.42689-ref32">32</xref>]。糖异生不仅是糖酵解的反向途径,还使用乳酸盐作为消耗糖酵解有害副产物的底物之一 [<xref ref-type="bibr" rid="hanspub.42689-ref33">33</xref>]。在肿瘤微环境中，T细胞的代谢途径可能受到葡萄糖竞争、细胞外乳酸积累和肿瘤细胞与T细胞之间相互作用的影响，所以这种葡萄糖代谢特征可能为治疗HCC提供了一个独特的机会。目前，HCC低氧治疗的主要策略是在肿瘤部位直接提供/产生氧以增加氧分压或间接降低缺氧诱导因子-1α的水平，并干扰缺氧诱导因子-1α相关的信号通路以降低低氧效果 [<xref ref-type="bibr" rid="hanspub.42689-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.42689-ref35">35</xref>]。然而，这些方法大多处于早期开发阶段，需要更多时间来评估它们在HCC疗法中的可用性。肿瘤性酸中毒可以通过减少产酸量、增加耗酸量和提供外部酸碱度缓冲液的方式调解，例如通过抑制糖酵解和使用乳酸作为底物，增加糖异生可以减少酸的产生和增加酸的消耗，质子泵/转运蛋白的靶向治疗也可以减少酸的产生，但是需要进行更多的基础研究和临床试验 [<xref ref-type="bibr" rid="hanspub.42689-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.42689-ref37">37</xref>]。对于免疫抑制，目前针对PD-1或CTLA-4的检查点阻断疗法已经在HCC患者中显示出初步的疗效，但是只有部分患者对其有反应，所以还需要进一步的研究。目前针对“抗沃伯格效应”的策略主要是针对糖酵解中涉及的关键转运蛋白和酶,然而，增加糖异生可以同时抑制糖酵解，这将成为“抗沃伯格效应”的新目标，但是还需要临床试验进行验证 [<xref ref-type="bibr" rid="hanspub.42689-ref38">38</xref>] [<xref ref-type="bibr" rid="hanspub.42689-ref39">39</xref>]。</p><p>虽然近年来我们对HBV相关肝癌的免疫发病机制有所了解，但控制这种疾病的确切机制还需要进一步研究。CD8+细胞毒性T淋巴细胞(CTLs)的产生在HBV相关肝癌的抗肿瘤免疫反应中起着重要作用，其免疫应答由HBV病毒载量、肿瘤抗原性以及肿瘤微环境的平衡所决定的，尤其是肿瘤微环境中的相关免疫抑制细胞、细胞因子以及能量异常代谢的调节作用增加了HBV相关肝癌的抗肿瘤免疫机制的复杂性。基于这些进展，针对HBV相关的HCC的增强CD8+T细胞抗肿瘤免疫反应的潜在策略可能会改善HBV相关HCC的预后以及生存期。</p></sec></sec><sec id="s9"><title>文章引用</title><p>任丹丹,马金鑫. HBV相关肝癌的CD8+T细胞抗肿瘤免疫机制研究进展Research Progress on Anti-Tumor Immune Mechanism of CD8+T Cells in HBV-Related Hepatocellular Carcinoma[J]. 临床医学进展, 2021, 11(05): 2347-2354. https://doi.org/10.12677/ACM.2021.115338</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42689-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.42689-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.  
&lt;br&gt;https://doi.org/10.3322/caac.21332</mixed-citation></ref><ref id="hanspub.42689-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Xie, Y.H. (2017) Hepatitis B Virus-Associated Hepatocellular Carcinoma. Advances in Experimental Medicine and Biology, 1018, 11-21. &lt;br&gt;https://doi.org/10.1007/978-981-10-5765-6_2</mixed-citation></ref><ref id="hanspub.42689-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, R.X., Seto, W.K., Lai, C.L., et al. (2016) Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut and Liver, 10, 332-339. &lt;br&gt;https://doi.org/10.5009/gnl15257</mixed-citation></ref><ref id="hanspub.42689-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y.Y. and Tian, Z.G. (2019) HBV-Induced Immune Imbalance in the Development of HCC. Frontiers in Immunology, 10, 2048. &lt;br&gt;https://doi.org/10.3389/fimmu.2019.02048</mixed-citation></ref><ref id="hanspub.42689-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X.C., He, Q.F., Shen, H.Y., et al. (2019) Genetic and Phenotypic Difference in CD8 T Cell Exhaustion between Chronic Hepatitis B Infection and Hepatocellular Carcinoma. Journal of Medical Genetics, 56, 18-21.  
&lt;br&gt;https://doi.org/10.1136/jmedgenet-2018-105267</mixed-citation></ref><ref id="hanspub.42689-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Li, Z.L., Chen, G., Cai, Z.X., et al. (2019) Genomic and Transcriptional Profiling of Tumor Infiltrated CD8 T Cells Revealed Functional Heterogeneity of Antitumor Immunity in Hepatocellular Carcinoma. Oncoimmunology, 8, e1538436.  
&lt;br&gt;https://doi.org/10.1080/2162402X.2018.1538436</mixed-citation></ref><ref id="hanspub.42689-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Witjes, C.D., Ijzermans, J.N., Van Der Eijk, A.A., et al. (2011) Quantitative HBV DNA and AST Are Strong Predictors for Survival after HCC Detection in Chronic HBV Patients. Netherlands Journal of Medicine, 69, 508-513.</mixed-citation></ref><ref id="hanspub.42689-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Huang, S.Y., Xia, Y., Lei, Z.Q., et al. (2017) Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. Journal of the American College of Surgeons, 224, 283-293.e4. &lt;br&gt;https://doi.org/10.1016/j.jamcollsurg.2016.11.009</mixed-citation></ref><ref id="hanspub.42689-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tan, A.T. and Schreiber, S. (2020) Adoptive T-Cell Therapy for HBV-Associated HCC and HBV Infection. Antiviral Research, 176, Article ID: 104748. &lt;br&gt;https://doi.org/10.1016/j.antiviral.2020.104748</mixed-citation></ref><ref id="hanspub.42689-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gehring, A.J., Ho, Z.Z., Tan, A.T., et al. (2009) Profile of Tumor Antigen-Specific CD8 T Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Gastroenterology, 137, 682-690.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2009.04.045</mixed-citation></ref><ref id="hanspub.42689-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Inada, Y., Mizukoshi, E., Seike, T., et al. (2019) Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients with Hepatocellular Carcinoma. Hepatology, 69, 653-665.  
&lt;br&gt;https://doi.org/10.1002/hep.30212</mixed-citation></ref><ref id="hanspub.42689-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Yang, H.Y., Sun, L.J., Guan, A., et al. (2021) Unique TP53 Neoantigen and the Immune Microenvironment in Long- Term Survivors of Hepatocellular Carcinoma. Cancer Immunology, Immunotherapy, 70, 667-677.  
&lt;br&gt;https://doi.org/10.1007/s00262-020-02711-8</mixed-citation></ref><ref id="hanspub.42689-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Rong, Y.H., Dong, Z., Hong, Z.X., et al. (2017) Reactivity toward Bifidobacterium longum and Enterococcus hirae Demonstrate Robust CD8 T Cell Response and Better Prognosis in HBV-Related Hepatocellular Carcinoma. Experimental Cell Research, 358, 352-359. &lt;br&gt;https://doi.org/10.1016/j.yexcr.2017.07.009</mixed-citation></ref><ref id="hanspub.42689-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Donisi, C., Puzzoni, M., Ziranu, et al. (2020) Immune Checkpoint Inhibitors in the Treatment of HCC. Frontiers in Oncology, 10, Article ID: 601240. &lt;br&gt;https://doi.org/10.3389/fonc.2020.601240</mixed-citation></ref><ref id="hanspub.42689-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Elkhoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. &lt;br&gt;https://doi.org/10.1016/S0140-6736(17)31046-2</mixed-citation></ref><ref id="hanspub.42689-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Duffy, A.G., Uiahannan, S.V., Makorova, R.O., et al. (2017) Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 66, 545-551.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2016.10.029</mixed-citation></ref><ref id="hanspub.42689-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X.L., Li, M.G., Wang, X.H., et al. (2019) PD-1+ TIGIT+ CD8+ T Cells Are Associated with Pathogenesis and Progression of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Cancer Immunology, Immunotherapy, 68, 2041-2054. &lt;br&gt;https://doi.org/10.1007/s00262-019-02426-5</mixed-citation></ref><ref id="hanspub.42689-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Liu, F.R., Zeng, G.C., Zhou, S.T., et al. (2018) Blocking Tim-3 or/and PD-1 Reverses Dysfunction of Tumor-Infil- trating Lymphocytes in HBV-Related Hepatocellular Carcinoma. Bulletin du Cancer, 105, 493-501.  
&lt;br&gt;https://doi.org/10.1016/j.bulcan.2018.01.018</mixed-citation></ref><ref id="hanspub.42689-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Saeidi, A., Zandi, K., Cheok, Y.Y., et al. (2018) T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses. Frontiers in Immunology, 9, 2569.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2018.02569</mixed-citation></ref><ref id="hanspub.42689-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Otano, I., Escors, D., Schurich, A. et al. (2018) Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 26, 2553-2566. &lt;br&gt;https://doi.org/10.1016/j.ymthe.2018.08.013</mixed-citation></ref><ref id="hanspub.42689-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Lim, C.J., Lee, Y.H., Pan, L., et al. (2019) Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut, 68, 916-927. &lt;br&gt;https://doi.org/10.1136/gutjnl-2018-316510</mixed-citation></ref><ref id="hanspub.42689-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Trehanpati, N. and Vyas, A.K. (2017) Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer. Scandinavian Journal of Immunology, 85, 175-181. &lt;br&gt;https://doi.org/10.1111/sji.12524</mixed-citation></ref><ref id="hanspub.42689-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Song, G.H., Shi, Y., Zhang, M.Y., et al. (2020) Global Immune Characterization of HBV/HCV-Related Hepatocellular Carcinoma Identifies Macrophage and T-Cell Subsets Associated with Disease Progression. Cell Discovery, 6, 90.  
&lt;br&gt;https://doi.org/10.1158/1538-7445.TUMHET2020-PO-055</mixed-citation></ref><ref id="hanspub.42689-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Li, T.Y., Zhang, X.Y., Lv, Z., et al. (2020) Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma. BioMed Research International, 2020, Article ID: 6527192.  
&lt;br&gt;https://doi.org/10.1155/2020/6527192</mixed-citation></ref><ref id="hanspub.42689-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hsiao, Y.W., Chiu, L.T., Chen, C.H., et al. (2019) Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes (Basel), 10, 630.  
&lt;br&gt;https://doi.org/10.3390/genes10080630</mixed-citation></ref><ref id="hanspub.42689-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Shi, J.X., Wang, F.M., et al. (2020) Interleukin 22 Is Related to Development and Poor Prognosis of Hepatocellular Carcinoma. Clinics and Research in Hepatology and Gastroenterology, 44, 855-864.  
&lt;br&gt;https://doi.org/10.1016/j.clinre.2020.01.009</mixed-citation></ref><ref id="hanspub.42689-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Nishida, N. and Kudo, M. (2017) Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. Oncology, 92, 40-49. &lt;br&gt;https://doi.org/10.1159/000451015</mixed-citation></ref><ref id="hanspub.42689-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y.G., Zheng, D.H., Shi, M., et al. (2019) T Cell Dysfunction in Chronic Hepatitis B Infection and Liver Cancer: Evidence from Transcriptome Analysis. Journal of Medical Genetics, 56, 22-28.  
&lt;br&gt;https://doi.org/10.1136/jmedgenet-2018-105570</mixed-citation></ref><ref id="hanspub.42689-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Sanderson, S.M. and Locasale, J.W. (2018) Revisiting the Warburg Effect: Some Tumors Hold Their Breath. Cell Metabolism, 28, 669-670. &lt;br&gt;https://doi.org/10.1016/j.cmet.2018.10.011</mixed-citation></ref><ref id="hanspub.42689-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tian, H.N., Zhu, X.Y., Lv, Y., et al. (2020) Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect. Cancer Management and Research, 12, 5957-5974.  
&lt;br&gt;https://doi.org/10.2147/CMAR.S258196</mixed-citation></ref><ref id="hanspub.42689-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Sharabi, K., Tavares, C.D.J., Rines, A.K., et al. (2015) Molecular Pathophysiology of Hepatic Glucose Production. Molecular Aspects of Medicine, 46, 21-33. &lt;br&gt;https://doi.org/10.1016/j.mam.2015.09.003</mixed-citation></ref><ref id="hanspub.42689-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Bian, X.L., Chen, H.Z., Yang, P.B., et al. (2017) Nur77 Suppresses Hepatocellular Carcinoma via Switching Glucose Metabolism toward Gluconeogenesis through Attenuating Phosphoenolpyruvate Carboxykinase Sumoylation. Nature Communications, 8, Article No. 14420. &lt;br&gt;https://doi.org/10.1038/ncomms14420</mixed-citation></ref><ref id="hanspub.42689-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Singh, L., Aldosary, S., Saeedan, A.S., et al. (2018) Prolyl Hydroxylase 2: A Promising Target to Inhibit Hypoxia-Induced Cellular Metabolism in Cancer Cells. Drug Discovery Today, 23, 1873-1882.  
&lt;br&gt;https://doi.org/10.1016/j.drudis.2018.05.016</mixed-citation></ref><ref id="hanspub.42689-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.Y., Jiang, Y.Q., Zhang, M., et al. (2018) Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors. Accounts of Chemical Research, 51, 2502-2511. &lt;br&gt;https://doi.org/10.1021/acs.accounts.8b00214</mixed-citation></ref><ref id="hanspub.42689-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Jin, X., Yan, Y.Q., et al. (2017) Inhibiting Histone Deacetylases Suppresses Glucose Metabolism and Hepatocellular Carcinoma Growth by Restoring FBP1 Expression. Scientific Reports, 7, Article No. 43864.  
&lt;br&gt;https://doi.org/10.1038/srep43864</mixed-citation></ref><ref id="hanspub.42689-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Z.N., Tian, B. and Guo, X.L. (2017) Repositioning of Proton Pump Inhibitors in Cancer Therapy. Cancer Chemotherapy and Pharmacology, 80, 925-937. &lt;br&gt;https://doi.org/10.1007/s00280-017-3426-2</mixed-citation></ref><ref id="hanspub.42689-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Martinez, O.U.E., Ppeiris, P.M., Pestell, R.G., et al. (2017) Cancer Metabolism: A Therapeutic Perspective. Nature Reviews Clinical Oncology, 14, 11-31. &lt;br&gt;https://doi.org/10.1038/nrclinonc.2016.60</mixed-citation></ref><ref id="hanspub.42689-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Fortunato, S., Bononi, G.C., et al. (2018) An Update on Patents Covering Agents That Interfere with the Cancer Glycolytic Cascade. ChemMedChem, 13, 2251-2265. &lt;br&gt;https://doi.org/10.1002/cmdc.201800447</mixed-citation></ref></ref-list></back></article>